医疗服务提供者对物质使用障碍患者的污名。

IF 5.3 1区 医学 Q1 PSYCHIATRY
Addiction Pub Date : 2025-07-23 DOI:10.1111/add.70122
Carrigan L Parish, Daniel J Feaster, Harold A Pollack, Viviana E Horigian, Xiaoming Wang, Petra Jacobs, Margaret R Pereyra, Christina Drymon, Elizabeth Allen, Lauren K Gooden, Carlos Del Rio, Lisa R Metsch
{"title":"医疗服务提供者对物质使用障碍患者的污名。","authors":"Carrigan L Parish, Daniel J Feaster, Harold A Pollack, Viviana E Horigian, Xiaoming Wang, Petra Jacobs, Margaret R Pereyra, Christina Drymon, Elizabeth Allen, Lauren K Gooden, Carlos Del Rio, Lisa R Metsch","doi":"10.1111/add.70122","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>The overdose epidemic accounts for more than 89 000 deaths across the United States annually. Despite the availability of medications and therapies to treat substance use disorders (SUD), most people remain untreated. Stigma towards treating patients with SUD has been identified as a potential barrier to SUD treatment. This study aimed to quantify the prevalence and intensity of provider stigma towards patients with SUD, by substance use type and compared with other conditions, and its relationship to providers' clinical practices.</p><p><strong>Design: </strong>National probability sample survey (October 2020-October 2022).</p><p><strong>Setting: </strong>USA; online/paper questionnaire.</p><p><strong>Participants: </strong>Primary care (PCPs) and emergency medicine physicians (EMPs) and dentists randomly selected from the American Medical and Dental Associations. Data were collected from 1240 participants (Council of American Survey Research Organizations response rate 53.6%).</p><p><strong>Measurements: </strong>The main outcome was self-reported provider stigma towards people with SUD, assessed by the Medical Condition Regard Scale. Providers indicated their agreement with 11 statements concerning three SUD categories [opioids (OUD), stimulants, alcohol (AUD)], Type II diabetes, depressive disorder and HIV. Mixed models compared stigma levels across conditions and by clinician group. Clinicians were assessed about their screening, referral and treatment practices.</p><p><strong>Findings: </strong>The lowest stigma rating was for diabetes (mean = 23.2; standard deviation = 6.5) and the highest for stimulant use disorders (mean = 36.3; standard deviation = 10.7). Stigma towards OUD was statistically significantly higher than AUD [effect size (ES) = 0.49, 95% confidence interval (CI) = (0.42-0.57), P < 0.001], while stigma towards stimulant use disorders was statistically significantly higher than OUD [ES = 0.11, 95% CI = (-0.04 to 0.19), P < 0.004]. EMPs had statistically significantly higher stigma scores than PCPs (P < 0.001), while PCPs reported significantly higher stigma scores than did dentists (P < 0.014). Lower stigma scores were associated with provision of SUD referrals [ES = -0.37, 95% CI = (-0.66 to -0.07)], providing medications for OUD [stigma scores: AUD (ES = -0.44, 95% CI = [-0.73 to -0.15]), OUD (ES = -1.26, 95% CI = [-1.55 to -0.97]) and stimulant use disorder (ES = -0.73, 95% CI = [-1.02 to -0.44])] and having available SUD consultation [stigma scores: AUD (ES = -0.48, 95% CI = [-0.67 to -0.28]), OUD (ES = -0.51, 95% CI = [-0.86 to -0.37]) and stimulant use disorder (ES = -0.59, 95% CI = [-0.78 to -0.39])].</p><p><strong>Conclusions: </strong>Among US primary care and emergency medicine physician workforces, provider stigma towards substance use disorders appears to be higher than for opioid, stimulant and alcohol use disorders and negatively associated with providers' clinical practices.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Healthcare provider stigma toward patients with substance use disorders.\",\"authors\":\"Carrigan L Parish, Daniel J Feaster, Harold A Pollack, Viviana E Horigian, Xiaoming Wang, Petra Jacobs, Margaret R Pereyra, Christina Drymon, Elizabeth Allen, Lauren K Gooden, Carlos Del Rio, Lisa R Metsch\",\"doi\":\"10.1111/add.70122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>The overdose epidemic accounts for more than 89 000 deaths across the United States annually. Despite the availability of medications and therapies to treat substance use disorders (SUD), most people remain untreated. Stigma towards treating patients with SUD has been identified as a potential barrier to SUD treatment. This study aimed to quantify the prevalence and intensity of provider stigma towards patients with SUD, by substance use type and compared with other conditions, and its relationship to providers' clinical practices.</p><p><strong>Design: </strong>National probability sample survey (October 2020-October 2022).</p><p><strong>Setting: </strong>USA; online/paper questionnaire.</p><p><strong>Participants: </strong>Primary care (PCPs) and emergency medicine physicians (EMPs) and dentists randomly selected from the American Medical and Dental Associations. Data were collected from 1240 participants (Council of American Survey Research Organizations response rate 53.6%).</p><p><strong>Measurements: </strong>The main outcome was self-reported provider stigma towards people with SUD, assessed by the Medical Condition Regard Scale. Providers indicated their agreement with 11 statements concerning three SUD categories [opioids (OUD), stimulants, alcohol (AUD)], Type II diabetes, depressive disorder and HIV. Mixed models compared stigma levels across conditions and by clinician group. Clinicians were assessed about their screening, referral and treatment practices.</p><p><strong>Findings: </strong>The lowest stigma rating was for diabetes (mean = 23.2; standard deviation = 6.5) and the highest for stimulant use disorders (mean = 36.3; standard deviation = 10.7). Stigma towards OUD was statistically significantly higher than AUD [effect size (ES) = 0.49, 95% confidence interval (CI) = (0.42-0.57), P < 0.001], while stigma towards stimulant use disorders was statistically significantly higher than OUD [ES = 0.11, 95% CI = (-0.04 to 0.19), P < 0.004]. EMPs had statistically significantly higher stigma scores than PCPs (P < 0.001), while PCPs reported significantly higher stigma scores than did dentists (P < 0.014). Lower stigma scores were associated with provision of SUD referrals [ES = -0.37, 95% CI = (-0.66 to -0.07)], providing medications for OUD [stigma scores: AUD (ES = -0.44, 95% CI = [-0.73 to -0.15]), OUD (ES = -1.26, 95% CI = [-1.55 to -0.97]) and stimulant use disorder (ES = -0.73, 95% CI = [-1.02 to -0.44])] and having available SUD consultation [stigma scores: AUD (ES = -0.48, 95% CI = [-0.67 to -0.28]), OUD (ES = -0.51, 95% CI = [-0.86 to -0.37]) and stimulant use disorder (ES = -0.59, 95% CI = [-0.78 to -0.39])].</p><p><strong>Conclusions: </strong>Among US primary care and emergency medicine physician workforces, provider stigma towards substance use disorders appears to be higher than for opioid, stimulant and alcohol use disorders and negatively associated with providers' clinical practices.</p>\",\"PeriodicalId\":109,\"journal\":{\"name\":\"Addiction\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Addiction\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/add.70122\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Addiction","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/add.70122","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:美国每年有超过89000人死于过量用药。尽管有治疗药物使用障碍(SUD)的药物和疗法,但大多数人仍未得到治疗。对治疗SUD患者的耻辱感已被确定为SUD治疗的潜在障碍。本研究旨在通过物质使用类型和与其他条件的比较,量化提供者对SUD患者的耻辱感的患病率和强度,以及其与提供者临床实践的关系。设计:全国概率抽样调查(2020年10月- 2022年10月)。背景:美国;在线/纸质问卷。参与者:从美国医学和牙科协会随机选择的初级保健(pcp)和急诊医师(EMPs)以及牙医。数据收集自1240名参与者(美国调查研究组织理事会回复率53.6%)。测量:主要结果是自我报告的提供者对SUD患者的耻辱感,通过医疗状况关注量表进行评估。供应商表示,他们同意有关三种SUD类别[阿片类药物(OUD)、兴奋剂、酒精(AUD)]、II型糖尿病、抑郁症和艾滋病毒的11项声明。混合模型比较了不同条件和临床医生组的病耻感水平。临床医生对他们的筛查、转诊和治疗实践进行了评估。结果:最低的病耻感评分是糖尿病(平均= 23.2;标准偏差= 6.5),兴奋剂使用障碍最高(平均值= 36.3;标准差= 10.7)。对OUD的耻辱感在统计学上显著高于AUD[效应值(ES) = 0.49, 95%置信区间(CI) = (0.42-0.57)], P结论:在美国初级保健和急诊医师中,提供者对物质使用障碍的耻辱感似乎高于阿片类药物、兴奋剂和酒精使用障碍,并与提供者的临床实践负相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Healthcare provider stigma toward patients with substance use disorders.

Background and aims: The overdose epidemic accounts for more than 89 000 deaths across the United States annually. Despite the availability of medications and therapies to treat substance use disorders (SUD), most people remain untreated. Stigma towards treating patients with SUD has been identified as a potential barrier to SUD treatment. This study aimed to quantify the prevalence and intensity of provider stigma towards patients with SUD, by substance use type and compared with other conditions, and its relationship to providers' clinical practices.

Design: National probability sample survey (October 2020-October 2022).

Setting: USA; online/paper questionnaire.

Participants: Primary care (PCPs) and emergency medicine physicians (EMPs) and dentists randomly selected from the American Medical and Dental Associations. Data were collected from 1240 participants (Council of American Survey Research Organizations response rate 53.6%).

Measurements: The main outcome was self-reported provider stigma towards people with SUD, assessed by the Medical Condition Regard Scale. Providers indicated their agreement with 11 statements concerning three SUD categories [opioids (OUD), stimulants, alcohol (AUD)], Type II diabetes, depressive disorder and HIV. Mixed models compared stigma levels across conditions and by clinician group. Clinicians were assessed about their screening, referral and treatment practices.

Findings: The lowest stigma rating was for diabetes (mean = 23.2; standard deviation = 6.5) and the highest for stimulant use disorders (mean = 36.3; standard deviation = 10.7). Stigma towards OUD was statistically significantly higher than AUD [effect size (ES) = 0.49, 95% confidence interval (CI) = (0.42-0.57), P < 0.001], while stigma towards stimulant use disorders was statistically significantly higher than OUD [ES = 0.11, 95% CI = (-0.04 to 0.19), P < 0.004]. EMPs had statistically significantly higher stigma scores than PCPs (P < 0.001), while PCPs reported significantly higher stigma scores than did dentists (P < 0.014). Lower stigma scores were associated with provision of SUD referrals [ES = -0.37, 95% CI = (-0.66 to -0.07)], providing medications for OUD [stigma scores: AUD (ES = -0.44, 95% CI = [-0.73 to -0.15]), OUD (ES = -1.26, 95% CI = [-1.55 to -0.97]) and stimulant use disorder (ES = -0.73, 95% CI = [-1.02 to -0.44])] and having available SUD consultation [stigma scores: AUD (ES = -0.48, 95% CI = [-0.67 to -0.28]), OUD (ES = -0.51, 95% CI = [-0.86 to -0.37]) and stimulant use disorder (ES = -0.59, 95% CI = [-0.78 to -0.39])].

Conclusions: Among US primary care and emergency medicine physician workforces, provider stigma towards substance use disorders appears to be higher than for opioid, stimulant and alcohol use disorders and negatively associated with providers' clinical practices.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Addiction
Addiction 医学-精神病学
CiteScore
10.80
自引率
6.70%
发文量
319
审稿时长
3 months
期刊介绍: Addiction publishes peer-reviewed research reports on pharmacological and behavioural addictions, bringing together research conducted within many different disciplines. Its goal is to serve international and interdisciplinary scientific and clinical communication, to strengthen links between science and policy, and to stimulate and enhance the quality of debate. We seek submissions that are not only technically competent but are also original and contain information or ideas of fresh interest to our international readership. We seek to serve low- and middle-income (LAMI) countries as well as more economically developed countries. Addiction’s scope spans human experimental, epidemiological, social science, historical, clinical and policy research relating to addiction, primarily but not exclusively in the areas of psychoactive substance use and/or gambling. In addition to original research, the journal features editorials, commentaries, reviews, letters, and book reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信